• argenx presents additional Efgartigimod data from Global Phase 3 ADAPT Trial

    Monday October 5th 2020

  • Galapagos announces first dosing with Toledo compound GLPG3970 in psoriasis trial

    Wednesday September 30th 2020

  • Celyad Oncology announces clinical trial collaboration to evaluate CYAD-101 with KEYTRUDA® (pembrolizumab) in patients with Microsatellite Stable mCRC

    Tuesday September 29th 2020

  • Johnson & Johnson initiates Pivotal Global Phase 3 Clinical Trial of Janssen’s COVID-19 vaccine candidate

    Thursday September 24th 2020

  • Camel-IDS enters next stage with name change to PRECIRIX® and IND approval for CAM-H2 Phase I/II study

    Tuesday September 22nd 2020

  • Primary endpoint achieved with ziritaxestat in NOVESA trial in systemic sclerosis patients

    Friday September 11th 2020

  • Oxurion NV reports first patient dosed in Phase 2 study evaluating THR-149 for treatment of Diabetic Macular Edema (DME)

    Tuesday September 1st 2020

  • Precigen ActoBio announces positive topline results from Phase 1b study of AG019 ActoBiotics

    Tuesday August 11th 2020

  • Your news here?

  • Mithra announces shelf life extension for Myring™ to 36 months

    Tuesday August 4th 2020

  • Gilead en Galapagos kondigen positieve Europese CHMP opinie aan voor Jyseleca® (Filgotinib) voor de behandeling van volwassenen met matige tot ernstige reumatoïde artritis

    Friday July 24th 2020

  • Aligos Therapeutics and KU Leuven announce collaboration for the development of a therapeutic candidate targeting Coronavirus

    Thursday July 2nd 2020

Strategic Partners